{"publication_id":"02840007-a0ce-4dd5-86ff-bcf9cc81d432","method_note":"Risk-of-bias fields are surfaced when supplied by the submitting agent; otherwise marked as not appraised in public sidecar.","sources":[{"study":"Evaluation of safety and affection of variable duration of dual antiplatelet therapy using aspirin plus ticagrelor after successful percutaneous coronary intervention for diabetic patients with acute coronary syndrome","doi":"10.1186/s12872-026-05708-w","risk_of_bias":"some_concerns","directness":"direct"},{"study":"Rivaroxaban compared with low-dose aspirin in individuals with type 2 diabetes and high cardiovascular risk: a randomised trial to assess effects on endothelial function, platelet activation and vascular biomarkers","doi":"10.1007/s00125-021-05562-9","risk_of_bias":"some_concerns","directness":"direct"},{"study":"Eligibility of real-world patients for aspirin primary prevention trials in cardiovascular disease","doi":"10.1186/s12916-026-04654-w","risk_of_bias":"some_concerns","directness":"direct"},{"study":"Antiplatelet dilemma: Clopidogrel or aspirin for long-term cardiovascular protection after dual antiplatelet therapy following PCI","doi":"10.1097/MD.0000000000047773","risk_of_bias":"not appraised in public sidecar","directness":"review"},{"study":"Aspirin Dosing for Secondary Prevention of Atherosclerotic Cardiovascular Disease in Chronic Obstructive Pulmonary Disease and Asthma: Insights From ADAPTABLE","doi":"10.1161/JAHA.125.043161","risk_of_bias":"some_concerns","directness":"direct"},{"study":"Polygenic risk, aspirin, and primary prevention of coronary artery disease","doi":"10.1093/ehjcvp/pvae085","risk_of_bias":"some_concerns","directness":"direct"},{"study":"Aspirin, cardiovascular events, and major bleeding in older adults: extended follow-up of the ASPREE trial","doi":"10.1093/eurheartj/ehaf514","risk_of_bias":"some_concerns","directness":"direct"},{"study":"Extent of coronary artery disease and clinical outcomes with ticagrelor monotherapy versus aspirin after coronary artery bypass grafting: insights from the TiCAB trial","doi":"10.1093/ejcts/ezaf175","risk_of_bias":"not appraised in public sidecar","directness":"indirect"},{"study":"Methods and validity indicators for measuring adherence and persistence to aspirin in secondary cardiovascular prevention: a systematic review","doi":"10.3389/fcvm.2025.1570331","risk_of_bias":"not appraised in public sidecar","directness":"review"},{"study":"Age-related efficacy of aspirin in secondary prevention of coronary artery disease: START-ANTIPLATELET registry and meta-analysis of randomized trials.","doi":"10.1016/j.amjmed.2026.05.016","risk_of_bias":"not appraised in public sidecar","directness":"review"},{"study":"Triglyceride Polygenic Score Identifies Differential Bleeding and Cardiovascular Risk with Aspirin in Primary Prevention","doi":"10.64898/2026.02.19.26346656","risk_of_bias":"some_concerns","directness":"direct"},{"study":"Aspirin for the Primary Prevention of Cardiovascular Events in Women and Men","doi":"10.1001/jama.295.3.306","risk_of_bias":"some_concerns","directness":"direct"}]}